Intermittent claudication is a type of muscle pain especially in calf muscle during exercise, such as walking, and is relieved by a short period of rest due to lack of blood supply.

The global Intermittent Claudication market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Intermittent Claudication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intermittent Claudication.

Report Scope

The Intermittent Claudication market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Intermittent Claudication market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Intermittent Claudication companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Intermittent Claudication Market Report

Report Metric	Details
Report Name	Intermittent Claudication Market
CAGR	5%
Segment by Type	by Treatment Process Medication Therapies Revascularization by Drug Type ALD-301 DVC1-0101 K-134 LT-0101 PLX-PAD Tirasemtiv
Segment by Application	Hospitals Clinics Home Healthcare Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	I'ROM GROUP(DNAVEC Corporation), Nuo Therapeutics Inc., Kowa Company Ltd., LTT Bio-Pharma, Pluristem Therapeutics Inc., Nuo Therapeutics, Inc.(Aldagen, Inc.), Genovate Biotechnology Co., Ltd., Novartis AG, ID Pharma Co., Ltd, Helixmith Co., Ltd., G. Pohl-Boskamp GmbH & Co. KG
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Intermittent Claudication companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Intermittent Claudication Market report?

Ans: The main players in the Intermittent Claudication Market are I'ROM GROUP(DNAVEC Corporation), Nuo Therapeutics Inc., Kowa Company Ltd., LTT Bio-Pharma, Pluristem Therapeutics Inc., Nuo Therapeutics, Inc.(Aldagen, Inc.), Genovate Biotechnology Co., Ltd., Novartis AG, ID Pharma Co., Ltd, Helixmith Co., Ltd., G. Pohl-Boskamp GmbH & Co. KG

What are the Application segmentation covered in the Intermittent Claudication Market report?

Ans: The Applications covered in the Intermittent Claudication Market report are Hospitals, Clinics, Home Healthcare, Others

What are the Type segmentation covered in the Intermittent Claudication Market report?

Ans: The Types covered in the Intermittent Claudication Market report are by Treatment Process, Medication Therapies, Revascularization, by Drug Type, ALD-301, DVC1-0101, K-134, LT-0101, PLX-PAD, Tirasemtiv

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Treatment Process

1.2.1 Global Intermittent Claudication Market Size Growth Rate by Treatment Process: 2019 VS 2023 VS 2030

1.2.2 Medication Therapies

1.2.3 Revascularization

1.3 Market by Application

1.3.1 Global Intermittent Claudication Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Home Healthcare

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Intermittent Claudication Market Perspective (2019-2030)

2.2 Intermittent Claudication Growth Trends by Region

2.2.1 Global Intermittent Claudication Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Intermittent Claudication Historic Market Size by Region (2019-2024)

2.2.3 Intermittent Claudication Forecasted Market Size by Region (2025-2030)

2.3 Intermittent Claudication Market Dynamics

2.3.1 Intermittent Claudication Industry Trends

2.3.2 Intermittent Claudication Market Drivers

2.3.3 Intermittent Claudication Market Challenges

2.3.4 Intermittent Claudication Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Intermittent Claudication Players by Revenue

3.1.1 Global Top Intermittent Claudication Players by Revenue (2019-2024)

3.1.2 Global Intermittent Claudication Revenue Market Share by Players (2019-2024)

3.2 Global Intermittent Claudication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Intermittent Claudication Revenue

3.4 Global Intermittent Claudication Market Concentration Ratio

3.4.1 Global Intermittent Claudication Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Intermittent Claudication Revenue in 2023

3.5 Intermittent Claudication Key Players Head office and Area Served

3.6 Key Players Intermittent Claudication Product Solution and Service

3.7 Date of Enter into Intermittent Claudication Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Intermittent Claudication Breakdown Data by Type

4.1 Global Intermittent Claudication Historic Market Size by Type (2019-2024)

4.2 Global Intermittent Claudication Forecasted Market Size by Type (2025-2030)

5 Intermittent Claudication Breakdown Data by Application

5.1 Global Intermittent Claudication Historic Market Size by Application (2019-2024)

5.2 Global Intermittent Claudication Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Intermittent Claudication Market Size (2019-2030)

6.2 North America Intermittent Claudication Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Intermittent Claudication Market Size by Country (2019-2024)

6.4 North America Intermittent Claudication Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Intermittent Claudication Market Size (2019-2030)

7.2 Europe Intermittent Claudication Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Intermittent Claudication Market Size by Country (2019-2024)

7.4 Europe Intermittent Claudication Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Intermittent Claudication Market Size (2019-2030)

8.2 Asia-Pacific Intermittent Claudication Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Intermittent Claudication Market Size by Region (2019-2024)

8.4 Asia-Pacific Intermittent Claudication Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Intermittent Claudication Market Size (2019-2030)

9.2 Latin America Intermittent Claudication Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Intermittent Claudication Market Size by Country (2019-2024)

9.4 Latin America Intermittent Claudication Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Intermittent Claudication Market Size (2019-2030)

10.2 Middle East & Africa Intermittent Claudication Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Intermittent Claudication Market Size by Country (2019-2024)

10.4 Middle East & Africa Intermittent Claudication Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 I'ROM GROUP(DNAVEC Corporation)

11.1.1 I'ROM GROUP(DNAVEC Corporation) Company Detail

11.1.2 I'ROM GROUP(DNAVEC Corporation) Business Overview

11.1.3 I'ROM GROUP(DNAVEC Corporation) Intermittent Claudication Introduction

11.1.4 I'ROM GROUP(DNAVEC Corporation) Revenue in Intermittent Claudication Business (2019-2024)

11.1.5 I'ROM GROUP(DNAVEC Corporation) Recent Development

11.2 Nuo Therapeutics Inc.

11.2.1 Nuo Therapeutics Inc. Company Detail

11.2.2 Nuo Therapeutics Inc. Business Overview

11.2.3 Nuo Therapeutics Inc. Intermittent Claudication Introduction

11.2.4 Nuo Therapeutics Inc. Revenue in Intermittent Claudication Business (2019-2024)

11.2.5 Nuo Therapeutics Inc. Recent Development

11.3 Kowa Company Ltd.

11.3.1 Kowa Company Ltd. Company Detail

11.3.2 Kowa Company Ltd. Business Overview

11.3.3 Kowa Company Ltd. Intermittent Claudication Introduction

11.3.4 Kowa Company Ltd. Revenue in Intermittent Claudication Business (2019-2024)

11.3.5 Kowa Company Ltd. Recent Development

11.4 LTT Bio-Pharma

11.4.1 LTT Bio-Pharma Company Detail

11.4.2 LTT Bio-Pharma Business Overview

11.4.3 LTT Bio-Pharma Intermittent Claudication Introduction

11.4.4 LTT Bio-Pharma Revenue in Intermittent Claudication Business (2019-2024)

11.4.5 LTT Bio-Pharma Recent Development

11.5 Pluristem Therapeutics Inc.

11.5.1 Pluristem Therapeutics Inc. Company Detail

11.5.2 Pluristem Therapeutics Inc. Business Overview

11.5.3 Pluristem Therapeutics Inc. Intermittent Claudication Introduction

11.5.4 Pluristem Therapeutics Inc. Revenue in Intermittent Claudication Business (2019-2024)

11.5.5 Pluristem Therapeutics Inc. Recent Development

11.6 Nuo Therapeutics, Inc.(Aldagen, Inc.)

11.6.1 Nuo Therapeutics, Inc.(Aldagen, Inc.) Company Detail

11.6.2 Nuo Therapeutics, Inc.(Aldagen, Inc.) Business Overview

11.6.3 Nuo Therapeutics, Inc.(Aldagen, Inc.) Intermittent Claudication Introduction

11.6.4 Nuo Therapeutics, Inc.(Aldagen, Inc.) Revenue in Intermittent Claudication Business (2019-2024)

11.6.5 Nuo Therapeutics, Inc.(Aldagen, Inc.) Recent Development

11.7 Genovate Biotechnology Co., Ltd.

11.7.1 Genovate Biotechnology Co., Ltd. Company Detail

11.7.2 Genovate Biotechnology Co., Ltd. Business Overview

11.7.3 Genovate Biotechnology Co., Ltd. Intermittent Claudication Introduction

11.7.4 Genovate Biotechnology Co., Ltd. Revenue in Intermittent Claudication Business (2019-2024)

11.7.5 Genovate Biotechnology Co., Ltd. Recent Development

11.8 Novartis AG

11.8.1 Novartis AG Company Detail

11.8.2 Novartis AG Business Overview

11.8.3 Novartis AG Intermittent Claudication Introduction

11.8.4 Novartis AG Revenue in Intermittent Claudication Business (2019-2024)

11.8.5 Novartis AG Recent Development

11.9 ID Pharma Co., Ltd

11.9.1 ID Pharma Co., Ltd Company Detail

11.9.2 ID Pharma Co., Ltd Business Overview

11.9.3 ID Pharma Co., Ltd Intermittent Claudication Introduction

11.9.4 ID Pharma Co., Ltd Revenue in Intermittent Claudication Business (2019-2024)

11.9.5 ID Pharma Co., Ltd Recent Development

11.10 Helixmith Co., Ltd.

11.10.1 Helixmith Co., Ltd. Company Detail

11.10.2 Helixmith Co., Ltd. Business Overview

11.10.3 Helixmith Co., Ltd. Intermittent Claudication Introduction

11.10.4 Helixmith Co., Ltd. Revenue in Intermittent Claudication Business (2019-2024)

11.10.5 Helixmith Co., Ltd. Recent Development

11.11 G. Pohl-Boskamp GmbH & Co. KG

11.11.1 G. Pohl-Boskamp GmbH & Co. KG Company Detail

11.11.2 G. Pohl-Boskamp GmbH & Co. KG Business Overview

11.11.3 G. Pohl-Boskamp GmbH & Co. KG Intermittent Claudication Introduction

11.11.4 G. Pohl-Boskamp GmbH & Co. KG Revenue in Intermittent Claudication Business (2019-2024)

11.11.5 G. Pohl-Boskamp GmbH & Co. KG Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

I'ROM GROUP(DNAVEC Corporation)

Nuo Therapeutics Inc

Kowa Company Ltd

LTT Bio-Pharma

Pluristem Therapeutics Inc

Nuo Therapeutics, Inc.(Aldagen, Inc.)

Genovate Biotechnology Co., Ltd.

Novartis

ID Pharma Co Ltd

Helixmith Co., Ltd.

G.Pohl-Boskamp GmbH＆Co.KG

List of Tables

Table 1. Global Intermittent Claudication Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Medication Therapies

Table 3. Key Players of Revascularization

Table 4. Global Intermittent Claudication Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Intermittent Claudication Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Intermittent Claudication Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Intermittent Claudication Market Share by Region (2019-2024)

Table 8. Global Intermittent Claudication Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Intermittent Claudication Market Share by Region (2025-2030)

Table 10. Intermittent Claudication Market Trends

Table 11. Intermittent Claudication Market Drivers

Table 12. Intermittent Claudication Market Challenges

Table 13. Intermittent Claudication Market Restraints

Table 14. Global Intermittent Claudication Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Intermittent Claudication Market Share by Players (2019-2024)

Table 16. Global Top Intermittent Claudication Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intermittent Claudication as of 2023)

Table 17. Ranking of Global Top Intermittent Claudication Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Intermittent Claudication Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Intermittent Claudication Product Solution and Service

Table 21. Date of Enter into Intermittent Claudication Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Intermittent Claudication Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Intermittent Claudication Revenue Market Share by Type (2019-2024)

Table 25. Global Intermittent Claudication Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Intermittent Claudication Revenue Market Share by Type (2025-2030)

Table 27. Global Intermittent Claudication Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Intermittent Claudication Revenue Market Share by Application (2019-2024)

Table 29. Global Intermittent Claudication Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Intermittent Claudication Revenue Market Share by Application (2025-2030)

Table 31. North America Intermittent Claudication Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Intermittent Claudication Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Intermittent Claudication Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Intermittent Claudication Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Intermittent Claudication Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Intermittent Claudication Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Intermittent Claudication Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Intermittent Claudication Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Intermittent Claudication Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Intermittent Claudication Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Intermittent Claudication Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Intermittent Claudication Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Intermittent Claudication Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Intermittent Claudication Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Intermittent Claudication Market Size by Country (2025-2030) & (US$ Million)

Table 46. I'ROM GROUP(DNAVEC Corporation) Company Detail

Table 47. I'ROM GROUP(DNAVEC Corporation) Business Overview

Table 48. I'ROM GROUP(DNAVEC Corporation) Intermittent Claudication Product

Table 49. I'ROM GROUP(DNAVEC Corporation) Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 50. I'ROM GROUP(DNAVEC Corporation) Recent Development

Table 51. Nuo Therapeutics Inc. Company Detail

Table 52. Nuo Therapeutics Inc. Business Overview

Table 53. Nuo Therapeutics Inc. Intermittent Claudication Product

Table 54. Nuo Therapeutics Inc. Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 55. Nuo Therapeutics Inc. Recent Development

Table 56. Kowa Company Ltd. Company Detail

Table 57. Kowa Company Ltd. Business Overview

Table 58. Kowa Company Ltd. Intermittent Claudication Product

Table 59. Kowa Company Ltd. Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 60. Kowa Company Ltd. Recent Development

Table 61. LTT Bio-Pharma Company Detail

Table 62. LTT Bio-Pharma Business Overview

Table 63. LTT Bio-Pharma Intermittent Claudication Product

Table 64. LTT Bio-Pharma Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 65. LTT Bio-Pharma Recent Development

Table 66. Pluristem Therapeutics Inc. Company Detail

Table 67. Pluristem Therapeutics Inc. Business Overview

Table 68. Pluristem Therapeutics Inc. Intermittent Claudication Product

Table 69. Pluristem Therapeutics Inc. Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 70. Pluristem Therapeutics Inc. Recent Development

Table 71. Nuo Therapeutics, Inc.(Aldagen, Inc.) Company Detail

Table 72. Nuo Therapeutics, Inc.(Aldagen, Inc.) Business Overview

Table 73. Nuo Therapeutics, Inc.(Aldagen, Inc.) Intermittent Claudication Product

Table 74. Nuo Therapeutics, Inc.(Aldagen, Inc.) Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 75. Nuo Therapeutics, Inc.(Aldagen, Inc.) Recent Development

Table 76. Genovate Biotechnology Co., Ltd. Company Detail

Table 77. Genovate Biotechnology Co., Ltd. Business Overview

Table 78. Genovate Biotechnology Co., Ltd. Intermittent Claudication Product

Table 79. Genovate Biotechnology Co., Ltd. Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 80. Genovate Biotechnology Co., Ltd. Recent Development

Table 81. Novartis AG Company Detail

Table 82. Novartis AG Business Overview

Table 83. Novartis AG Intermittent Claudication Product

Table 84. Novartis AG Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 85. Novartis AG Recent Development

Table 86. ID Pharma Co., Ltd Company Detail

Table 87. ID Pharma Co., Ltd Business Overview

Table 88. ID Pharma Co., Ltd Intermittent Claudication Product

Table 89. ID Pharma Co., Ltd Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 90. ID Pharma Co., Ltd Recent Development

Table 91. Helixmith Co., Ltd. Company Detail

Table 92. Helixmith Co., Ltd. Business Overview

Table 93. Helixmith Co., Ltd. Intermittent Claudication Product

Table 94. Helixmith Co., Ltd. Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 95. Helixmith Co., Ltd. Recent Development

Table 96. G. Pohl-Boskamp GmbH & Co. KG Company Detail

Table 97. G. Pohl-Boskamp GmbH & Co. KG Business Overview

Table 98. G. Pohl-Boskamp GmbH & Co. KG Intermittent Claudication Product

Table 99. G. Pohl-Boskamp GmbH & Co. KG Revenue in Intermittent Claudication Business (2019-2024) & (US$ Million)

Table 100. G. Pohl-Boskamp GmbH & Co. KG Recent Development

Table 101. Research Programs/Design for This Report

Table 102. Key Data Information from Secondary Sources

Table 103. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Intermittent Claudication Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Intermittent Claudication Market Share by Type: 2023 VS 2030

Figure 3. Medication Therapies Features

Figure 4. Revascularization Features

Figure 5. Global Intermittent Claudication Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Intermittent Claudication Market Share by Application: 2023 VS 2030

Figure 7. Hospitals Case Studies

Figure 8. Clinics Case Studies

Figure 9. Home Healthcare Case Studies

Figure 10. Others Case Studies

Figure 11. Intermittent Claudication Report Years Considered

Figure 12. Global Intermittent Claudication Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Intermittent Claudication Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Intermittent Claudication Market Share by Region: 2023 VS 2030

Figure 15. Global Intermittent Claudication Market Share by Players in 2023

Figure 16. Global Top Intermittent Claudication Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intermittent Claudication as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Intermittent Claudication Revenue in 2023

Figure 18. North America Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Intermittent Claudication Market Share by Country (2019-2030)

Figure 20. United States Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Intermittent Claudication Market Share by Country (2019-2030)

Figure 24. Germany Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Intermittent Claudication Market Share by Region (2019-2030)

Figure 32. China Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Intermittent Claudication Market Share by Country (2019-2030)

Figure 40. Mexico Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Intermittent Claudication Market Share by Country (2019-2030)

Figure 44. Turkey Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Intermittent Claudication Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. I'ROM GROUP(DNAVEC Corporation) Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 47. Nuo Therapeutics Inc. Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 48. Kowa Company Ltd. Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 49. LTT Bio-Pharma Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 50. Pluristem Therapeutics Inc. Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 51. Nuo Therapeutics, Inc.(Aldagen, Inc.) Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 52. Genovate Biotechnology Co., Ltd. Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 53. Novartis AG Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 54. ID Pharma Co., Ltd Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 55. Helixmith Co., Ltd. Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 56. G. Pohl-Boskamp GmbH & Co. KG Revenue Growth Rate in Intermittent Claudication Business (2019-2024)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Respiratory Infection Diagnostic Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-39D3651

Wed Apr 17 00:00:00 UTC 2024

Add to Cart

Global Internal Neuromodulation Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-24F2529

Wed Apr 17 00:00:00 UTC 2024

Add to Cart

Global Colon Cancer Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-31C5944

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global CAR T-Cell Immunotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10J13802

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions